Non-small cell lung cancer · line 2 · Entrectinib monotherapy (STARTRK-2) — ROS1+ NSCLC (CNS-active)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-ENTRECTINIB-NSCLC`

ID	`IND-NSCLC-2L-ROS1-POST-CRIZ-ENTRECTINIB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025` `SRC-STARTRK2-DRILON-2020`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track 2L ROS1+ NSCLC post-crizotinib. Repotrectinib (TRIDENT-1) is separate Indication for solvent-front-resistant or post-entrectinib disease.

Used By

Algorithms

ALGO-NSCLC-METASTATIC-2L - ALGO-NSCLC-METASTATIC-2L